What is the BSMC ETF?

Estrella Immunopharma develops innovative T-cell therapies for blood cancers and tumors, focusing on candidates EB103 and EB104 in preclinical trials.

Will the BSMC ETF go up?

According to Danelfin AI, the BSMC ETF has today an AI Score of 8/10 (Buy rating), because its probability of beating the ETF universe in 3 months (65.13%) is +2.54% vs. the average probability (62.59%) of all US-listed ETFs.

Is it a good time to buy, sell, or hold the BSMC ETF right now?

The BSMC ETF has today a Buy rating (AI Score 8/10), according to Danelfin AI. Its probability of beating the ETF universe in 3 months (65.13%) is +2.54% vs. the average probability (62.59%) of all US-listed ETFs, based on our AI-powered analysis.

Is the BSMC ETF overbought?

The Danelfin AI Technical Score for BSMC ETF is 7/10, which is a Buy based solely on technical indicators.

What was the price range of the BSMC ETF over the past 12 months?

The BSMC ETF price range over the past 12 months has been $30.71 - $39.44.

What is going on with the BSMC ETF in the last 3 months?

The BSMC ETF performance in the last quarter has been +8.53%.

Does the BSMC ETF offer dividend payments?

Yes, the BSMC ETF dividend yield is 0.92%.

What is the AUM of the BSMC ETF?

The BSMC ETF has 166.44M in total assets under management (AUM).

How much does it cost to invest in the BSMC ETF?

The BSMC ETF total expense ratio is 0.71%.

Brandes U.S. Small-Mid Cap Value ETF BSMC ETF AI-powered analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

BSMC AI-Powered ETFs Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Buy

BRANDES US SMALL-MID CAP (BSMC) has a AI Score of 8/10 (Buy) because, according to an overall analysis, it has a probability advantage of +2.54% of beating the ETF universe (an equal-weight index of all US-listed ETFs) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed ETF (62.59%) and the probability of BSMC (65.13%) of outperforming the ETF universe in the next 3 months, as determined by Danelfin AI's comprehensive analysis.

Average probability of any US-listed ETF of beating the ETF universe (3M)62.59%
BSMC probability advantage of beating the ETF universe (3M)+2.54%
BSMC probability of beating the ETF universe (3M)65.13%

BSMC probability advantage of beating the ETF universe (3M): +2.54%

The AI-powered overall analysis of BRANDES US SMALL-MID CAP (BSMC) is based on the 33 fundamental, technical, and sentiment features that had the greatest impact on ETF performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of BSMC:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	ETF Brand	-	N/A	+1.02%
Technical	Chart Pattern (180d)	figure_131	N/A	+0.85%
Sentiment	ETF Investment Segment	-	N/A	+0.76%
Technical	Chart Pattern (90d)	figure_5	N/A	+0.75%
Technical	Technicals Impact (Long Tail)	-	N/A	-0.65%
Fundamental	Price/Book (MRQ)	1.68		+0.62%
Fundamental	Flows to AUM YTD	5.37%		+0.61%
Technical	Alpha 1M	0.06%		-0.56%
Sentiment	ETF Issuer	-	N/A	-0.52%
Technical	Alpha 6M	0.04%		+0.39%
Technical	Upgrade to unlock			-0.31%
Technical	Upgrade to unlock			+0.27%
Technical	Upgrade to unlock			-0.27%
Technical	Upgrade to unlock			-0.24%
Technical	Upgrade to unlock			-0.21%

Rest of Alpha Signals: +0.02%

BSMC probability advantage of beating the ETF universe (3M)Total:+2.54%
BSMC AI Score

Significant changes Vs previous day

BSMC Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$39.44
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

BSMC Proven Buy Signal & Price Forecast

This is the price chart for BSMC from January 2, 2026 until today. The chart indicates, in green, the 58 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

BSMC Average Past Performance & Win Rate

Three months after its 297 Buy signals since July 2026, BSMC had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

297 Past BSMC Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+10.55%
Average Alpha				-4.38%
Win Rate (% Positive Perf.)				94.93%
% Positive Alpha				28.26%

BSMC Frequently Asked Questions

What is the BSMC ETF?
Estrella Immunopharma develops innovative T-cell therapies for blood cancers and tumors, focusing on candidates EB103 and EB104 in preclinical trials.
Will the BSMC ETF go up?
Is it a good time to buy, sell, or hold the BSMC ETF right now?
Is the BSMC ETF overbought?
What was the price range of the BSMC ETF over the past 12 months?
What is going on with the BSMC ETF in the last 3 months?
Does the BSMC ETF offer dividend payments?
What is the AUM of the BSMC ETF?
How much does it cost to invest in the BSMC ETF?

BSMC ETF Profile

Estrella Immunopharma, Inc. is a biopharmaceutical organization at the preclinical stage, primarily centered on the development of innovative T-cell therapies aimed at combating blood cancers and solid tumors within the United States. Leading its product portfolio are two key candidates: EB103 and EB104. EB103, currently in preclinical trials, shows promising potential for addressing diffuse large B-cell lymphoma. Meanwhile, EB104 has been conceived for treating both diffuse large B-cell lymphoma and acute lymphocytic leukemia. In an inspired strategic alliance with Imugene Limited, Estrella Immunopharma is pioneering new avenues for solid tumor treatments. This collaboration ensures leveraging Imugene's product candidate CF33-CD19t alongside EB103 to forge a robust medical paradigm that firmly stands against such health concerns. Emeryville, California serves as the operational hub for Estrella Immunopharma, Inc., illustrating an enduring commitment to transforming the face of medical solutions through groundbreaking therapeutical research and development.

Asset ClassEquity
Asset Class Style-
FocusExtended Market
General Region-
Specific Region-

Asset Class
Asset Class Style
Focus
General Region
Specific Region

BSMC Top 10 Focus ETFs

Extended Market

	ETF	AI Score
1	MCHSMatthews China Discovery Active ETF
2	FFSMFidelity Fundamental Small-Mid Cap ETF
3	DFATDimensional U.S. Targeted Value ETF
4	VXFVanguard Extended Market ETF
5	JMEEJPMorgan Small & Mid Cap Enhanced Equity ETF
6	FSMDFidelity Small-Mid Multifactor ETF
7	CNXTVanEck ChiNext ETF
8	TMSLT. Rowe Price Small-Mid Cap ETF
9	SMMDiShares Russell 2500 ETF
10	SMIGBahl & Gaynor Small/Mid Cap Income Growth ETF

	ETF	AI Score

BSMC ETF AI Analysis